责任编辑：钟离 格隆汇12月30日丨百利天恒(688506.SH)公布，公司本次回购的股份将在未来适宜时机全部用于实施员 工持股计划或股权激励。回购股份金额不低于人民币10,000万元（含），不超过人民币20,000万元 （含）。回购股份价格不超过人民币546元/股（含）。 财经频道更多独家策划、专家专栏，免费查阅>> ...

Suspension and Resumption - Tianpu Co., Ltd. has suspended trading due to a significant deviation of its stock price from the company's fundamentals. The company has no plans to engage in artificial intelligence-related business and has not signed any framework cooperation agreements with shareholder Zhonghao Xinying. There are no asset injection plans related to Zhonghao Xinying [1] Share Buybacks - Zhongju High-tech plans to repurchase shares worth between 300 million to 600 million yuan for cancellation and reduction of registered capital [2] - Baili Tianheng intends to repurchase shares valued at 100 million to 200 million yuan [2] Mergers and Acquisitions - Shengxin Lithium Energy plans to acquire 30% equity of Qicheng Mining for 2.08 billion yuan, aiming for 100% ownership. Qicheng Mining's subsidiary, Huirong Mining, holds mining rights for the Muro Lithium Mine, which has confirmed Li2O resources of 989,600 tons with an average grade of 1.62%, making it one of the highest-grade lithium mines in Sichuan, with a production scale of 3 million tons per year [3] - Mingde Bio plans to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in cash. The target company is one of the early adopters of international first aid concepts and technologies, focusing on emergency rescue business [3] - Yilake Co., Ltd. intends to acquire 51% equity of Minmetals Salt Lake for 4.605 billion yuan [3] - CITIC Special Steel's wholly-owned subsidiary, Taifu Technology, plans to acquire 100% equity of Fujing Special Co., Ltd. from Guangzhou Airport for 1.51 billion yuan. Fujing Special is one of the world's top three independent steel traders [3] - China National Pharmaceutical plans to acquire 70% equity of Zezheng Pharmaceutical for 525 million yuan. Zezheng Pharmaceutical specializes in the research and development of modified new drugs and complex formulations [3] External Investments and Daily Operations - Wanli Stone plans to establish a joint venture to develop and operate the Kuerdai Molybdenum Uranium polymetallic mine resources [4] - China Nonferrous Metals plans to invest 1.741 billion yuan in the expansion project of a lead-zinc mine with an annual capacity of 1.65 million tons [5] - Taihe Technology plans to transform its original lithium iron phosphate production facility to produce sodium iron phosphate, achieving an annual production capacity of 10,000 tons [5] - Zhaofeng Co., Ltd. intends to invest 1.53 billion yuan in the industrialization project of embodied intelligent robots and high-end precision components for automotive intelligent driving [5] - Datang Power plans to increase its investment in Datang Nuclear Power Company by 617 million yuan for projects including the Liaoning Xudabao Nuclear Power Project and Ningde Second Nuclear Power [5] - Huaxia Airlines plans to purchase three A320 series aircraft, with an estimated transaction amount of approximately 2.763 billion to 2.976 billion yuan [6] - Jingce Electronics plans to sell multiple semiconductor front-end testing equipment to customers, totaling 571 million yuan [7] - Tianyuan Co., Ltd. plans to invest 1.483 billion yuan in a project to build an annual production capacity of 100,000 tons of titanium dioxide using the chloride method [8] - Baiwei Storage plans to acquire 380,000 shares of Niu Xin Semiconductor for 2 million yuan, with the National Integrated Circuit Fund Phase II holding a 6.76% stake in the latter [9] - Jinpan Technology has signed a contract for a data center project with overseas clients, amounting to 98.992 million USD [9] Performance Changes - Zijin Mining expects a net profit attributable to shareholders of approximately 51 billion to 52 billion yuan for the fiscal year 2025, representing a year-on-year increase of about 59% to 62%. The sales prices of gold, copper, and silver have increased year-on-year [10]

证券代码：688506 证券简称：百利天恒 公告编号：2025-093 四川百利天恒药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：不低于人民币 10,000 万元（含），不超过人民币 20,000 万 元（含）。 ● 回购股份资金来源：四川百利天恒药业股份有限公司（以下简称"公司"） 自有资金和/或自筹资金。 ● 回购股份用途：本次回购的股份将在未来适宜时机全部用于实施员工持股 计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告日后 3 年内使 用完毕已回购股份，尚未使用的已回购股份将予以注销。如国家对相关政策作调 整，则本回购方案按调整后的政策实行。 关于以集中竞价交易方式回购股份的预案 ● 回购股份价格：不超过人民币 546 元/股（含），该价格不超过董事会通过回 购决议前 30 个交易日公司 A 股股票交易均价的 150%。 ● 回购股份方式：集中竞价交易方式。 ● 回购股份期限：自公司董事会审议通过本次股份回购方案之日起12 个月内。 ● 相关股东是否存 ...

本次会议按照《公司法》和《公司章程》的有关规定，对以下议案进行审议， 经表决，会议决议如下： 证券代码：688506 证券简称：百利天恒 公告编号：2025-092 四川百利天恒药业股份有限公司 第五届董事会第五次会议决议公告 1、审议通过《关于以集中竞价交易方式回购公司股份方案的议案》 基于对公司未来发展的信心和对公司价值的认可，为充分激发公司员工积极性， 持续建立公司长效激励机制，并增强投资者对公司的投资信心，紧密结合公司利益、 股东利益与员工利益，综合考虑公司股价情况、经营情况、财务状况等，公司拟通 过集中竞价交易方式回购公司股份，回购股份将在未来合适时机用于员工持股计划 或股权激励。同时，公司董事会授权公司管理层全权办理本次回购股份相关事宜。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 四川百利天恒药业股份有限公司（以下简称"公司"）第五届董事会第五次会 议（以下简称"本次会议"）于 2025 年 12 月 30 日在公司会议室召开。本次会议以 现场及通讯表决方式召开，应出席董事 9 名 ...

Group 1 - The company plans to repurchase its shares through centralized bidding, with a total repurchase amount ranging from 100 million to 200 million yuan [1] - The maximum repurchase price is set at 546 yuan per share [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - The repurchase period is set for 12 months from the date the board of directors approves the share repurchase plan [1]

Core Viewpoint - The company, Baili Tianheng (688506.SH), announced a share repurchase plan with a total amount between 100 million and 200 million yuan, with a maximum repurchase price of 546 yuan per share. The repurchased shares will be used for employee stock ownership plans or equity incentives at an appropriate time in the future. Any unutilized repurchased shares within three years will be canceled [1]. Group 1 - The company plans to repurchase shares through centralized bidding [1] - The total repurchase amount is set between 100 million and 200 million yuan [1] - The maximum repurchase price is capped at 546 yuan per share [1] Group 2 - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] - Any unutilized repurchased shares after three years will be canceled [1]

南财智讯12月30日电，百利天恒公告，公司拟以集中竞价交易方式回购股份，回购资金总额不低于1.00 亿元、不超过2.00亿元，资金来源为公司自有资金和/或自筹资金。本次回购股份价格不超过546元/股， 回购的股份将在未来适宜时机全部用于实施员工持股计划或股权激励。若公司在股份回购实施结果暨股 份变动公告日后3年内未使用完毕已回购股份，未使用的股份将予以注销。回购期限为自董事会审议通 过方案之日起12个月内。截至2025年9月30日，公司总资产为123.19亿元，归属于上市公司股东的净资 产为71.71亿元，本次回购资金上限占相应财务数据比例较小，不会对公司日常经营、财务状况及偿债 能力产生重大影响。 ...

每经AI快讯，12月30日，百利天恒(688506.SH)公告称，公司拟以集中竞价交易方式回购公司股份，回 购金额不低于1亿元且不超过2亿元，回购价格不超过546元/股。回购的股份将在未来适宜时机全部用于 实施员工持股计划或股权激励。若公司未能在股份回购实施结果暨股份变动公告日后3年内使用完毕已 回购股份，尚未使用的已回购股份将予以注销。 ...

百利天恒公告，拟以1亿元-2亿元回购公司股份，回购价格不超过546元/股。 ...

Core Viewpoint - The article discusses the strong recovery of the innovative drug sector in Hong Kong and A-share markets in 2025, highlighting the performance of companies like BaiLi TianHeng and the implications of its debt financing plan [3][5]. Group 1: Company Performance - BaiLi TianHeng's stock price has surged over 10 times since its listing, reflecting strong market interest [5]. - The company plans to issue debt financing tools worth up to 100 billion RMB to support its operations, including R&D, debt repayment, and potential acquisitions [7]. - In 2024, BaiLi TianHeng reported a significant revenue of 58.23 billion RMB and a net profit of 37.08 billion RMB, largely due to an 800 million USD upfront payment from a partnership with BMS [9]. Group 2: Financial Situation - The company experienced a net loss of 4.95 billion RMB in the first three quarters of 2025, following the decline of one-time licensing revenue [9]. - BaiLi TianHeng's cash flow from operating activities was negative at -18.92 billion RMB for the same period, indicating high reliance on external funding [11]. - R&D expenditures reached 17.72 billion RMB in the first three quarters of 2025, a 90.23% increase year-on-year, accounting for 85.79% of revenue [11]. Group 3: Market Strategy - The company attempted to go public in Hong Kong to establish an A+H dual financing platform but delayed its IPO due to unfavorable market conditions [11][12]. - Following the unsuccessful IPO, BaiLi TianHeng shifted focus to debt financing to alleviate funding pressures [12]. - The stock price fell by 2.95% on December 29, indicating market skepticism regarding the company's future performance [12].